Enter any ticker symbol here to see the live quote & chart tools in action Ticker:

Benefits: / Your filings are automatically published to your site as they are filed. Investors don't have to leave your site to see filings. Product Description Once a report has been filed with the SEC it will be available on the website. SEC Filings Section 16 Filings Only   NOVADEL PHARMA INC filed this 10-K on 10/27/2006. Click on link to view section or document 1. Entire Document including Exhibit(s) 2. 10-K PAGE: 1 - UNITED STATES PAGE: 2 - PAGE: 3 - NOVADEL PHARMA INC. PAGE: 4 - SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PAGE: 5 - PAGE: 6 - PRODUCT DEVELOPMENT PAGE: 7 - PAGE: 8 - Comparison to Imitrex Nasal Spray Published Data PAGE: 9 - BUSINESS DEVELOPMENT PAGE: 10 - LICENSE AND SUPPLY AGREEMENT WITH PAR PHARMACEUTICAL, INC. PAGE: 11 - PATENTED AND PATENT PENDING DELIVERY SYSTEMS PAGE: 12 - MANUFACTURING PAGE: 13 - Section 505(b)(2) New Drug Applications PAGE: 14 - The Hatch-Waxman Act PAGE: 15 - Other Regulatory Requirements PAGE: 16 - Reimbursement PAGE: 17 - PATENTS AND PROTECTION OF PROPRIETARY INFORMATION PAGE: 18 - PAGE: 19 - PAGE: 20 - EMPLOYEES PAGE: 21 - WE ARE A PRE-COMMERCIALIZATION COMPANY, HAVE A LIMITED OPERATING HISTORY AND HAVE NOT GENERATED ANY PAGE: 22 - OUR ADDITIONAL FINANCING REQUIREMENTS COULD RESULT IN DILUTION TO EXISTING STOCKHOLDERS. PAGE: 23 - THERE ARE CERTAIN INTERLOCKING RELATIONSHIPS AND POTENTIAL CONFLICTS OF INTEREST. PAGE: 24 - OUR BUSINESS AND REVENUE IS DEPENDENT ON THE SUCCESSFUL DEVELOPMENT OF OUR PRODUCTS. PAGE: 25 - WE MUST COMPLY WITH GOOD MANUFACTURING PRACTICES. PAGE: 26 - COMPLIANCE WITH CHANGING REGULATION OF CORPORATE GOVERNANCE AND PUBLIC DISCLOSURE MAY RESULT IN ADDI PAGE: 27 - LIMITED PRODUCT LIABILITY INSURANCE COVERAGE MAY AFFECT OUR BUSINESS. PAGE: 28 - THE CLINICAL TRIAL AND REGULATORY APPROVAL PROCESS FOR OUR PRODUCTS IS EXPENSIVE AND TIME CONSUMING, PAGE: 29 - WE EXPECT TO FACE UNCERTAINTY OVER REIMBURSEMENT AND HEALTHCARE REFORM. PAGE: 30 - OUR STRATEGY INCLUDES ENTERING INTO COLLABORATION AGREEMENTS WITH THIRD PARTIES FOR CERTAIN OF OUR P PAGE: 31 - EVEN IF WE OBTAIN PATENTS TO PROTECT OUR PRODUCTS, THOSE PATENTS MAY NOT BE SUFFICIENTLY BROAD AND O PAGE: 32 - INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES COULD LIMIT OUR ABILITY TO MARKET OUR PRODUCTS. PAGE: 33 - WE ARE DEPENDENT ON EXISTING MANAGEMENT. PAGE: 34 - THE MARKET PRICE OF OUR STOCK AND OUR EARNINGS MAY BE ADVERSELY AFFECTED BY MARKET VOLATILITY. PAGE: 35 - PENNY STOCK REGULATIONS MAY IMPOSE CERTAIN RESTRICTIONS ON MARKETABILITY OF OUR SECURITIES. PAGE: 36 - SHARES ELIGIBLE FOR FUTURE SALE MAY ADVERSELY AFFECT THE MARKET. PAGE: 37 - PROVISIONS OF OUR CERTIFICATE OF INCORPORATION AND DELAWARE LAW COULD DETER A CHANGE OF OUR MANAGEME PAGE: 38 - THE UNCERTAINTY CREATED BY CURRENT ECONOMIC CONDITIONS AND POSSIBLE TERRORIST ATTACKS AND MILITARY R PAGE: 39 - ITEM 2. PROPERTIES. PAGE: 40 - PART II PAGE: 41 - ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA. PAGE: 42 - ITEM 7. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. PAGE: 43 - PAGE: 44 - PAGE: 45 - CRITICAL ACCOUNTING POLICIES PAGE: 46 - RESULTS OF OPERATIONS PAGE: 47 - PAGE: 48 - FISCAL YEARS ENDED JULY 31, 2005 AND 2004 PAGE: 49 - LIQUIDITY AND CAPITAL RESOURCES PAGE: 50 - OFF-BALANCE SHEET ARRANGEMENTS PAGE: 51 - ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. PAGE: 52 - PART III PAGE: 53 - William F. Hamilton PAGE: 54 - AUDIT COMMITTEE PAGE: 55 - ITEM 11. EXECUTIVE COMPENSATION. PAGE: 56 - OPTION GRANTS IN LAST FISCAL YEAR PAGE: 57 - EMPLOYMENT AGREEMENTS AND CHANGE IN CONTROL ARRANGEMENTS PAGE: 58 - Gary A. Shangold, M.D. PAGE: 59 - Michael E.B. Spicer. PAGE: 60 - Barry C. Cohen PAGE: 61 - COMPENSATION OF DIRECTORS PAGE: 62 - Cash Compensation PAGE: 63 - ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED MATTERS. PAGE: 64 - Stock Ownership of Directors, Management and Certain Beneficial Owners PAGE: 65 - Stock Ownership of Directors and Management PAGE: 66 - ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS. PAGE: 67 - ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES. PAGE: 68 - Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Au PAGE: 69 - All Other Services PAGE: 70 - INDEX TO EXHIBITS PAGE: 71 - PAGE: 72 - PAGE: 73 - PAGE: 74 - SIGNATURES PAGE: 75 - PAGE: 76 - INDEX TO FINANCIAL STATEMENTS PAGE: 77 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM PAGE: 78 - NOVADEL PHARMA INC. PAGE: 79 - NOVADEL PHARMA INC. PAGE: 80 - NOVADEL PHARMA INC. PAGE: 81 - NOVADEL PHARMA INC. PAGE: 82 - NOVADEL PHARMA INC. PAGE: 83 - PAGE: 84 - PAGE: 85 - NOTE 4 - PROPERTY AND EQUIPMENT PAGE: 86 - NOTE 5 - RELATED PARTY TRANSACTIONS PAGE: 87 - NOTE 7 - COMMITMENTS AND CONTINGENCIES PAGE: 88 - PAGE: 89 - NOTE 8 INVESTMENT IN EQUITY SECURITY PAGE: 90 - NOTE 10 - INCOME TAXES PAGE: 91 - NOTE 11 - STOCK OPTIONS AND WARRANTS PAGE: 92 - NOTE 12 THREATENED LITIGATION PAGE: 93 - NOTE 13 VALUATION AND QUALIFYING ACCOUNTS PAGE: 94 - PAGE: 95 - INDEX TO EXHIBITS PAGE: 96 - PAGE: 97 - PAGE: 98 - 3. EX-23 - Consents of experts and counsel PAGE: 1 - Consent of Independent Registered Public Accounting Firm 4. EX-31 - Certifications required under Section 302 of the Sarbanes-Oxley Act of 2002 PAGE: 1 - 5. EX-31 - Certifications required under Section 302 of the Sarbanes-Oxley Act of 2002 PAGE: 1 - 6. EX-32 - Certifications required under Section 906 of the Sarbanes-Oxley Act of 2002 PAGE: 1 - Quote & Chart Package Basic Stock Chart Basic Stock Quote Embedded Quote / Chart Embedded Full Quote / Chart Interactive Chart Intraday Chart Pop Up Quote Scrolling Ticker You are viewing our Quote and Chart Demo using ticker symbol NVDL

T 800.650.1211     F 888.329.6696     E info@stockgroup.com   © 2004 Stockgroup Media Inc.    Disclaimer